Immunohistochemical evaluation of cox-1 and cox-2 expression in keloid and hypertrophic scar

American Journal of Dermatopathology

Volumn 36, Issue 4, 2014, Pages 311-317

  Abdou, Asmaa G ^a   Maraee, Alaa H ^a   Abd Elsattar Saif, Hala F ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Cox 1; Cox 2; Hypertrophic sca; Keloid

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LOCALIZATION; EPIDERMIS; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; HYPERTROPHIC SCAR; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; KELOID; KERATINOCYTE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN BIOPSY; BIOPSY; CASE CONTROL STUDY; CHILD; METABOLISM; PATHOLOGY; SKIN; UPREGULATION; WOUND HEALING; YOUNG ADULT;

ADOLESCENT; ADULT; BIOPSY; CASE-CONTROL STUDIES; CHILD; CICATRIX, HYPERTROPHIC; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KELOID; KERATINOCYTES; MALE; SKIN; UP-REGULATION; WOUND HEALING; YOUNG ADULT;

EID: 84899641406     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3182a27b83     Document Type: Article

References (30)

1. Yu H, Bock O, Bayat A, et al. Decreased expression of inhibitory SMAD 6 and SMAD 7 in keloid scarring. J Plast Recost Aesthet Surg. 2006;5: 221-229.
2. Rossiello L, D'Andrea F, Grella R, et al. Differential expression of cyclooxygenases in hypertrophic scar and keloid tissues. Wound Repair Regen. 2009;17:750-757.
3. Sobolewski C, Cerella C, Dicato M, et al. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol. 2010;15:6619-6629.
4. Stratton R, Shiwen X. Role of prostaglandins in fibroblast activation and fibrosis. J Cell Commun Signal. 2010;4:75-77.
5. Wilgus TA, Vodovotz Y, Vittadini E, et al. Reduction of scar formation in full-thickness wounds with topical celecoxib treatment. Wound Repair Regen. 2003;11:25-34.
6. Ong CT, Khoo YT, Tan EK, et al. Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion. J Pathol. 2007;211:95-108.
7. Louw L. The keloid phenomenon: progress toward a solution. Clin Anat. 2007;20:3-14.
8. Diaz A, Chepenik KP, Korn JH, et al. Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res. 1998;241:222-229.
9. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl. 1997;49:15-19.
10. Wallace JL, Bak A, McKnight W, et al. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology. 1998;115:101-109.
11. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002;68-69:165-175.
12. Abd-El-Aleem SA, Ferguson MW, Appleton I, et al. Expression of cyclooxygenase isoforms in normal human skin and chronic venous ulcers. J Pathol. 2001;195:616-623
13. Al-Attar A, Mess S, Thomassen JM. Keloid pathogenesis and treatment. Plast Reconstr Surg. 2006;117:286-300.
14. Lee JY, Yang CC, Chao SC, et al. Histopathological differential diagnosis of keloid and hypertrophic scar. Am J Dermatopathol. 2004;26: 379-384.
15. Abdou AG, Maraee AH, Al-Bara AM, et al. Immunohistochemical expression of TGF-b1 in keloids and hypertrophic scars. Am J Dermatopathol. 2011;33:84-91.
16. Kössi J, Peltonen J, Uotila P, et al. Differential effects of hexoses and sucrose, and platelet-derived growth factor isoforms on cyclooxygenase- 1 and -2 mRNA expression in keloid, hypertrophic scar and granulation tissue fibroblasts. Arch Dermatol Res. 2001;293:126-132.
17. Bin L, Wei-feng L, Bai-cheng Z, et al. Study of expression and relationship between PTEN and COX-2 in pathological scars. Chin J Mod Oper Surg. 2009;13:162-166.
18. Horrillo R, Planagumá A, González-Périz A, et al. Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor. J Pharmacol Exp Ther. 2007;323:778-786.
19. Lappi-Blanco E, Kaarteenaho-Wiik R, Maasilta PK, et al. COX-2 is widely expressed in metaplastic epithelium in pulmonary fibrous disorders. Am J Clin Pathol. 2006;126:717-724.
20. Kanekura T, Higashi Y, Kanzaki T. Cyclooxygenase-2 expression and prostaglandin E2 biosynthesis are enhanced in scleroderma fibroblasts and inhibited by UVA irradiation. J Rheumatol. 2001; 28:1568-1572.
21. Parfenova H, Parfenov VN, Shlopov BV, et al. Dynamics of nuclear localization sites for COX-2 in vascular endothelial cells. Am J Physiol Cell Physiol. 2001;28:166-178.
22. Thanan R, Murata M, Ma N, et al. Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer. Mediators Inflamm. 2012;2012:165879.
23. Martin P. Wound healing aiming for a perfect skin regeneration. Science. 1997;276:75-81.
24. Hakvoort T, Altun V, van Zuijlen PP, et al. Transforming growth factorb1, 2 and 3, basic fibroblast growth factor and vascular endothelial expression in keratinocytes of burn scars. Eur Cytokine Netw. 2000;11: 233-239.
25. Zhang G, Ladehoff D, Xu Y, et al. Stable overexpression of TGF- in a transitional cell carcinoma cell line: impact on fibronectin production. J Urol. 1998;160:230-235.
26. Pandit A, Ashar R, Feldman D. The effect of TGF-beta delivered through a collagen scaffold on wound healing. J Invest Surg. 1999;12:89-100.
27. Li Y, Huard J. Differentiation of muscle-derived cells into myofibroblasts in injured skeletal muscle. Am J Pathol. 2002;161:895-907.
28. Kuwano K, Hagimoto N, Nakanishi Y. The role of apoptosis in pulmonary fibrosis. Histol Histopathol. 2004;19:867-881.
29. Suematsu M, Suzuki H, Delano FA, et al. The inflammatory aspect of the microcirculation inhypertension: oxidative stress, leukocytes/endothelial interaction, apoptosis. Microcirculation. 2002;9:259-276.
30. Madaan S, Abel PD, Chaudhary KS, et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int. 2000 86:736-741.